Biohaven Pharma (BHVN) Misses Q3 EPS by 10c

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance